Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Roflumilast + Vemurafenib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | melanoma | sensitive | Roflumilast + Vemurafenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of Roflumilast and Zelboraf (vemurafenib) inhibited colony formation and resulted in decreased spheroid size of melanoma cells harboring BRAF V600E in culture, and led to greater inhibition of tumor growth in a cell line xenograft model compared to Zelboraf (vemurafenib) alone (PMID: 39574163). | 39574163 |
PubMed Id | Reference Title | Details |
---|---|---|
(39574163) | PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors. | Full reference... |